JP2010501598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501598A5 JP2010501598A5 JP2009525881A JP2009525881A JP2010501598A5 JP 2010501598 A5 JP2010501598 A5 JP 2010501598A5 JP 2009525881 A JP2009525881 A JP 2009525881A JP 2009525881 A JP2009525881 A JP 2009525881A JP 2010501598 A5 JP2010501598 A5 JP 2010501598A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- nhch
- interfering substituent
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 230000002452 interceptive effect Effects 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 102100038239 Protein Churchill Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- HUAGJEFCGABVOP-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(N(C)C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O HUAGJEFCGABVOP-FMDGEEDCSA-N 0.000 claims 1
- PPAIMZHKIXDJRN-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O PPAIMZHKIXDJRN-FMDGEEDCSA-N 0.000 claims 1
- IKRLXWRFEXJEQI-JGKVKWKGSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O IKRLXWRFEXJEQI-JGKVKWKGSA-N 0.000 claims 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 1
- 208000023697 ABri amyloidosis Diseases 0.000 claims 1
- 208000017227 ADan amyloidosis Diseases 0.000 claims 1
- 206010058284 Allergy to arthropod sting Diseases 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 claims 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010019315 Heart transplant rejection Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023439 Kidney transplant rejection Diseases 0.000 claims 1
- 206010024715 Liver transplant rejection Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010051604 Lung transplant rejection Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000013152 interventional procedure Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 0 *C[C@]1OC2SC(*)=NC2[C@@](*)[C@@]1O Chemical compound *C[C@]1OC2SC(*)=NC2[C@@](*)[C@@]1O 0.000 description 2
- SJOFQKYWIQVOLP-QJVVIPRHSA-N CCNC(SC(CC12)OC(C3)(C3O)[C@H]3O)=N[C@H]1C2C3O Chemical compound CCNC(SC(CC12)OC(C3)(C3O)[C@H]3O)=N[C@H]1C2C3O SJOFQKYWIQVOLP-QJVVIPRHSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84119606P | 2006-08-31 | 2006-08-31 | |
| US60/841,196 | 2006-08-31 | ||
| US89566307P | 2007-03-19 | 2007-03-19 | |
| US60/895,663 | 2007-03-19 | ||
| PCT/CA2007/001554 WO2008025170A1 (en) | 2006-08-31 | 2007-08-31 | Selective glycosidase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013123917A Division JP5771237B2 (ja) | 2006-08-31 | 2013-06-12 | 選択的グリコシダーゼ阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010501598A JP2010501598A (ja) | 2010-01-21 |
| JP2010501598A5 true JP2010501598A5 (enExample) | 2010-10-21 |
| JP5380293B2 JP5380293B2 (ja) | 2014-01-08 |
Family
ID=39135489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525881A Expired - Fee Related JP5380293B2 (ja) | 2006-08-31 | 2007-08-31 | 選択的グリコシダーゼ阻害剤およびその使用 |
| JP2013123917A Expired - Fee Related JP5771237B2 (ja) | 2006-08-31 | 2013-06-12 | 選択的グリコシダーゼ阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013123917A Expired - Fee Related JP5771237B2 (ja) | 2006-08-31 | 2013-06-12 | 選択的グリコシダーゼ阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8334310B2 (enExample) |
| EP (2) | EP2322529B1 (enExample) |
| JP (2) | JP5380293B2 (enExample) |
| AU (1) | AU2007291870B2 (enExample) |
| CA (1) | CA2661582C (enExample) |
| WO (1) | WO2008025170A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2599843C (en) * | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| JP5380293B2 (ja) | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010012107A1 (en) * | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012014786A1 (en) * | 2010-07-30 | 2012-02-02 | Semiconductor Energy Laboratory Co., Ltd. | Semicondcutor device and manufacturing method thereof |
| US8901087B2 (en) | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) * | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) * | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| WO2012126091A1 (en) * | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) * | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| WO2012129651A1 (en) * | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| RU2625308C2 (ru) * | 2011-06-27 | 2017-07-13 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| WO2013025452A1 (en) * | 2011-08-18 | 2013-02-21 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| WO2013028715A1 (en) | 2011-08-25 | 2013-02-28 | Merck Patent Gmbh | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| WO2013166654A1 (en) * | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| CN104395323B (zh) * | 2012-05-08 | 2017-08-01 | 默沙东公司 | 可透过性糖苷酶抑制剂及其用途 |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| KR20150079711A (ko) * | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| BR112015021708A2 (pt) | 2013-03-06 | 2017-08-29 | Protalix Ltd | Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa |
| PL2970272T3 (pl) | 2013-03-14 | 2019-09-30 | Merck Patent Gmbh | Inhibitory glikozydazowe |
| TW201613861A (en) * | 2014-02-12 | 2016-04-16 | Amicus Therapeutics Inc | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC |
| WO2016025790A1 (en) * | 2014-08-15 | 2016-02-18 | The Johns Hopkins University | Use of uap inhibitors to inhibit flux through the hexosamine biosynthetic pathway |
| SG11201701315VA (en) | 2014-08-28 | 2017-03-30 | Asceneuron Sa | Glycosidase inhibitors |
| US10269832B2 (en) * | 2014-10-10 | 2019-04-23 | Joled Inc. | Thin film transistor substrate, method for manufacturing thin film transistor substrate, and display panel |
| ES2809728T3 (es) | 2015-06-24 | 2021-03-05 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| CA3014572C (en) | 2016-02-25 | 2023-10-03 | Asceneuron S.A. | Acid addition salts of piperazine derivatives |
| MX2018010192A (es) | 2016-02-25 | 2019-01-31 | Asceneuron S A | Inhibidores de glucosidasa. |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| EP3585783A2 (en) | 2016-02-25 | 2020-01-01 | Asceneuron SA | Sulfoximine glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| WO2019037861A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | ANNOTATED GLYCOSIDASE INHIBITORS |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| AU2019324522B2 (en) | 2018-08-22 | 2024-11-14 | Asceneuron S. A. | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2020169804A1 (en) | 2019-02-22 | 2020-08-27 | Asceneuron Sa | Fused glycosidase inhibitors |
| KR20240035456A (ko) | 2021-07-05 | 2024-03-15 | 페레르 인터내쇼날 에스.에이. | 글리코시다제 저해제를 포함하는 의약 |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
| WO2025131275A1 (en) | 2023-12-20 | 2025-06-26 | Asceneuron Sa | (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS423200Y1 (enExample) | 1964-02-21 | 1967-02-24 | ||
| JPH01180894A (ja) | 1988-01-07 | 1989-07-18 | Wako Pure Chem Ind Ltd | アミノ糖誘導体の新規な製造法 |
| JPH023200A (ja) | 1988-06-10 | 1990-01-08 | Mitsubishi Electric Corp | 半導体集積回路装置のテスト回路 |
| JPH07316178A (ja) | 1994-05-25 | 1995-12-05 | Sankyo Co Ltd | 糖アミノオキサゾリン類 |
| JPH09132585A (ja) | 1995-11-10 | 1997-05-20 | Shin Etsu Chem Co Ltd | 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法 |
| US6774140B1 (en) | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| EP1181274B1 (en) | 1999-05-11 | 2010-11-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| JP4036755B2 (ja) | 2001-03-14 | 2008-01-23 | 電気化学工業株式会社 | ヒアルロン酸又はヒアルロン酸誘導体の製造法 |
| JP4233262B2 (ja) | 2001-03-14 | 2009-03-04 | 生化学工業株式会社 | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 |
| JP4866515B2 (ja) | 2001-07-02 | 2012-02-01 | 生化学工業株式会社 | 糖オキサゾリン誘導体の製造方法 |
| CA2526173A1 (en) | 2003-05-22 | 2004-12-02 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| CN1548053A (zh) | 2003-05-23 | 2004-11-24 | 华晶基因技术有限公司 | 黄芩甙作为治疗焦虑症的药物的新用途 |
| EP1713485A4 (en) | 2004-01-20 | 2007-09-19 | Optimer Pharmaceuticals Inc | TREATMENT OF DEGENERATIVE TREATMENTS IN A MAMMALIAN WITH GLYCOSIDASE INHIBITORS |
| EP1734821A4 (en) | 2004-04-14 | 2011-07-06 | Uab Research Foundation | ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK |
| CA2599843C (en) | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| JP5380293B2 (ja) | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| WO2010012107A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110301217A1 (en) | 2008-09-16 | 2011-12-08 | David Jaro Vocadlo | Selective Glycosidase Inhibitors and Uses Thereof |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061971A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| RU2625308C2 (ru) | 2011-06-27 | 2017-07-13 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
-
2007
- 2007-08-31 JP JP2009525881A patent/JP5380293B2/ja not_active Expired - Fee Related
- 2007-08-31 WO PCT/CA2007/001554 patent/WO2008025170A1/en not_active Ceased
- 2007-08-31 EP EP11157096.6A patent/EP2322529B1/en not_active Not-in-force
- 2007-08-31 US US12/438,882 patent/US8334310B2/en not_active Expired - Fee Related
- 2007-08-31 EP EP07800577A patent/EP2057171A4/en not_active Withdrawn
- 2007-08-31 AU AU2007291870A patent/AU2007291870B2/en not_active Ceased
- 2007-08-31 CA CA2661582A patent/CA2661582C/en not_active Expired - Fee Related
-
2012
- 2012-08-22 US US13/591,927 patent/US8962664B2/en not_active Expired - Fee Related
-
2013
- 2013-06-12 JP JP2013123917A patent/JP5771237B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501598A5 (enExample) | ||
| WO2008025170B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| JP2014524911A5 (enExample) | ||
| JP2014501740A5 (enExample) | ||
| RU2014102232A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP2013541596A5 (enExample) | ||
| JP2011529858A5 (enExample) | ||
| JP2011529857A5 (enExample) | ||
| RU2013134345A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP2012502884A5 (enExample) | ||
| Kikuchi et al. | Potent antimalarial febrifugine analogues against the plasmodium malaria parasite | |
| JP5551708B2 (ja) | アゼピノ［４，５−ｂ］インドール化合物およびその使用方法 | |
| KR102108586B1 (ko) | 투과성 글리코시다제 억제제 및 그의 용도 | |
| RU2015120556A (ru) | Ингибиторы гликозидаз и их применения | |
| TWI781177B (zh) | 作為C5a抑制劑之6-5稠合環 | |
| CN105143221A (zh) | 用于治疗炎性障碍的化合物及其药物组合物 | |
| RU2013126531A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| US10836759B2 (en) | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | |
| JP2018537483A (ja) | ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法 | |
| KR20140063700A (ko) | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 | |
| JP2011524867A (ja) | 糖質コルチコイド模倣物質、その製造方法、医薬組成物、及びその使用 | |
| TW202024073A (zh) | 作為jak抑制劑之二甲基胺基氮雜環丁烷醯胺 | |
| TW202024075A (zh) | 作為jak抑制劑之5至7員雜環醯胺 | |
| US20210138092A1 (en) | Selective ligands for tau aggregates | |
| US9464103B2 (en) | Spirocyclic sulfones as gamma secretase inhibitors |